Azzet reports on three stocks with price moving updates today
Betr 24.5pc turnover jumps, launches 10pc buy-back
Betr Entertainment (ASX:BBT) was trading 13% higher at the open after the pure-play digital wagering small capitalisation stock reported a 24.5% rise in turnover for the second quarter (Q2) of the 2026 financial year (FY26) driven by 163,504 active customers, despite the net win margin being temporarily compressed by customer-friendly results during the Spring Racing Carnival.
The market also reacted favourably to management’s commitment scale in the Australian market through organic growth, disciplined mergers and acquisitions (M&A) and announcement of an on-market share buy-back of up to 10% of its ordinary shares, funded from cash reserves.
The board views this approach to capital management as an efficient way to address an undervalued share price while maintaining capacity to pursue consolidation and partnership opportunities.
Although customer-friendly results over the Spring Racing Carnival appear to have adversely impacted the net win margin - 1.2 percentage points below the target range – they have since returned to trend of 11% in December, with January trading maintaining higher levels.
Management also told the market the company was pursuing growth organically and via M&A, with discussions ongoing with several industry players.
As of late 2025, discussions between Betr and Entain’s Australian and NZ operations - including Ladbrokes and Neds - were described as informal.
Meanwhile, Entain is facing significant legal action from the financial regulator the Australian Transaction Reports and Analysis Centre (AUSTRAC) regarding anti-money laundering concerns, with a Federal Court hearing scheduled for 30 November 2026.
As punters may recall, last year the company launched a hostile takeover of online bookmaker Pointsbet (ASX: PBH) but lost out to Japan-based Mixi.
The market update follows revelations last month that Chief Financial Officer Darren Holley was stepping down from his position, effective 31 December.
For the full year ending 30 June 30, Betr reported revenue of $132 million, a net loss of $14.8 million and a strong net cash position of $71.5 million.
The company holds cash and cash equivalents of $104.9 million and total debt of $38.95 million.
Betr Entertainment has a market cap. of $271 million; the share price is down 13% in one year and up 30% in the last month.
The stock’s shares appear to be in a strong near-term rally within a longer-term bearish trend.
The 200-day moving average is downward sloping and implies that there has been limited demand for this stock.
While it is too early to tell whether this rally could be the beginning of a new long-term trend, the stochastic oscillator is overbought and tells us that this level of upward momentum is unsustainable.
The consensus recommendation is Strong Buy.
Rumble Resources rallies after updating on Western Queen project
Shares in Rumble Resources (ASX: RTR) were trading 16% higher at noon after the junior explorer reported multiple high-grade gold intercepts from diamond drilling at its Western Queen project in Western Australia, highlighted by an exceptional intercept at Western Queen Central.
The drilling success suggests Western Queen's high-grade gold mineralisation extends well beyond the resource boundaries with nine out of 11 holes returning significant gold intercepts.
The standout result from hole WQDD052 returned 5.8m @ 30.72g/t Au from 314.6m, one of the highest-grade intercepts reported at the project.
Managing Director Peter Harold told the market the exceptional result from the Rumble Resources gold drilling programme demonstrated the continued success of the company's exploration strategy.
"The +30g/t hit at Western Queen Central is spectacular and indicates that there could be more higher-grade mineralisation at Western Queen,” he said.
The drilling program also intersected tungsten mineralisation, flagging the possible upside in the project’s tungsten resource, with further assay results due later in January.
Tungsten is classified as a critical mineral due to its essential applications in high-strength steel alloys, electronics and semiconductors, defence applications, and renewable energy infrastructure.
Recent ASX drilling updates have shown tungsten values including:
• 5.9m @ 0.30% WO3 from 201m (WQDD033)
• 1.24% WO3 over 1m from 215m (WQDD038)
• 6.24m @ 0.30% WO3 from 223.76m (WQDD040)
Meanwhile, the tungsten resource stands at 4.31Mt @ 0.31% WO3 for 13,200 tonnes WO3 while geological studies confirm tungsten mineralisation predates gold formation, creating two distinct revenue streams from the same mining operation.
The company recently raised around $9 million and as at 30 September held about $5 million in cash.
Rumble Resources has a market cap. of $75 million; the share price is up 45% over one year and 46% in the last month.
The stock appears to be in a strong bullish trend confirmed by multiple indicators.
Consensus does not cover this stock.
Neuren Pharmaceuticals soars after updating on Daybue sales
Shares in Neuren Pharmaceuticals (ASX: NEU) were trading over 6% higher this afternoon following a meaningful update by its partner Acadia this morning.
The California-based biopharmaceutical company told the market that global net sales of its Rett syndrome treatment Daybue were expected to hit US $700 million ($1.05 billion) by 2028.
Much of the expected expansion is being attributed to the U.S. rollout of a new STIX formulation, expanded sales teams and potential European approval.
To the uninitiated, Neuren and Acadia Pharmaceuticals are long-term strategic partners in the development and commercialisation of treatments for rare neurodevelopmental disorders, specifically Rett syndrome and Fragile X syndrome.
Underpinning the relationship is a worldwide exclusive licensing agreement within which Neuren acts as the developer/licensor and Acadia as the commercialisation partner.
Since its U.S. launch in 2023, more than 2000 patients have been treated, with 12-month persistency rising to 55%.
Daybue STIX is rolling out in America now, with full availability expected by the second quarter.
Meanwhile, the oral solution has been approved in Israel, while a phase three trial in Japan is ongoing, with top-line results due between the Q4 2026 and Q1 2027.
Acadia also continues its LOTUS real-world study with over 300 patients, tracking outcomes and expanding usage insights.
Today’s announcement follows Neuren reporting a 24% rise in quarterly royalties from Daybue in November 2025.
Since April 2025 the stock’s share price has more than doubled due to strong sales of the Rett syndrome drug Daybue and positive developments in its second drug candidate, NNZ-2591.
NNZ-2591 is in Phase 2 clinical trials for four other rare neurodevelopmental disorders each with orphan drug status.
The company reported a significant increase in profit and strong cash reserves, with first half (H1) 2025 profit after tax at $15.0 million - up from $8.0 million in H1 2024 - reinforcing its financial strength and ability to fund future development.
The company is expected to release its next full year results around 26 February 2026 for the financial year ending December 2025.
Neuren Pharmaceuticals has a market cap. of $2.6 billion; the share price is up 71% in one year and up 9.5% in the last week.
While the stock’s 200-day moving average is trending upwards and highlights long-term investor interest in the stock, the 20-day moving average is falling as upwards momentum wanes.
There is consensus recommendation for this stock.
